Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02262533 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
A Phase 1 study of N/A - Healthy Subjects, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02262533: Completed Phase 1 study of N/A - Healthy Subjects, sponsored by Bristol-Myers Squibb.
NCT02262533 is a Phase 1 study of N/A - Healthy Subjects that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02262533, a Phase 1 study of N/A - Healthy Subjects, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
Primary Outcome
Blood samples for Atenolol PK were collected on days 1-3 of each period (Treatment B and C). Blood samples for Apixaban PK were collected on days 1-4 of each period (Treatment A and C)
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG Atenolol
Study Locations (1)
New Jersey
- Bms Clinical Research Center - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
What the finished NCT02262533 record still lists
NCT02262533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with N/A - Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.
NCT02262533 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02262533 about?
NCT02262533 is a clinical study titled "Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects". The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
What is the current status of trial NCT02262533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-06. Estimated completion is 2007-06.
What conditions does trial NCT02262533 study?
This clinical trial studies the following conditions: N/A - Healthy Subjects.
What interventions are being tested in trial NCT02262533?
The interventions under investigation include: Apixaban (DRUG), Atenolol (DRUG).
Who is sponsoring clinical trial NCT02262533?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02262533 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for N/A - Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02262533's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia